GI 5005

Drug Profile

GI 5005

Alternative Names: GI-5005; Tarmogen

Latest Information Update: 14 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlobeImmune
  • Class Antivirals; Hepatitis C vaccines
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 03 Nov 2010 GlobeImmune receives grants under the Federal Therapeutics Discovery Projects programme for GI 5005 development in Hepatitis C
  • 30 Oct 2010 Efficacy data from a phase IIb trial (GI-5005-02) in Hepatitis C presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2010)
  • 28 Oct 2010 GlobeImmune expands phase IIb trial (GI-5005-02) for treatment-naive Hepatitis C to include patients with IL28B T/T genotype
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top